Published 13:16 IST, July 31st 2020
Bill Gates finds 'no cost-benefit ratio' in reopening bars until vaccine availability
Bill Gates said that he can’t see the cost-benefit ratio of reopening of bars and restaurants as the United States continue to witness a surge in COVID-19 cases
Advertisement
Bill Gates, principal founder of Microsoft Corporation, said that he can’t see cost-benefit ratio of reopening of bars and restaurants as United States continue to witness a surge in coronavirus cases. Speaking at TIME100 Talks on July 30, Gates said that schools should be opened up if COVID-19 cases get very low but re’s reason to let bar and restaurants open until re is a vaccine.
“If numbers get very low, n you can do opening up and things like schools – particularly for young children – should be opened up,” said Gates as US President Donald Trump pushes for reopening of schools.
co-chair of Bill and Melinda Gates Foundation highlighted that transmission risk in bars remain high because people talk loudly and remain close to each or. While he ackwledged that number of infections in initial hotspots of coronavirus has declined dramatically, he indicated that virus response has t been “as tasteful as we might like to be.”
Advertisement
Vaccine research contribution
Bill and Melinda Gates Foundation has donated millions of dollars for coronavirus vaccine and treatment research programmes. In February, foundation pledged to donate $100 million to coronavirus vaccine research and treatment efforts and months later, it pledged ditional $1.6 billion to Gavi vaccine alliance, a public-private global health partnership with goal of increasing access to immunisation in poor countries.
Advertisement
Recently, Gates said that South Korean pharmaceutical company SK Bioscience may be capable of producing 200 million coronavirus vaccine doses by June 2021. In a letter to South Korean President Moon Jae-in, Gates sought close cooperation with Asian nation but presidential office has t elaborated on it.
In May, Gates Foundation provided $3.6 million to SK Bioscience to accelerate development of coronavirus vaccines. Apart from developing its own vaccine, pharma company has also taken contract from AstraZeneca Plc to manufacture its vaccine AZD1222, which is currently undergoing a large-scale Phase III human trial.
Advertisement
Advertisement
(Im: AP)
13:16 IST, July 31st 2020